Literature DB >> 19457163

Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.

Claire Gibrat1, Martine Saint-Pierre, Mélanie Bousquet, Daniel Lévesque, Claude Rouillard, Francesca Cicchetti.   

Abstract

Animal models are invaluable tools to study neurodegenerative disorders but a general consensus on the most accurate rodent model of Parkinson's disease has not been reached. Here, we examined how different methods of MPTP administration influence the degeneration of the dopaminergic (DA) system. Adult male C57BL/6 mice were treated with the same cumulative dose of MPTP following four distinct procedures: (i) subacute i.p. injections; (ii) 28-day chronic s.c. infusion; (iii) 28-day chronic i.p. infusion; and (iv) 14-day chronic i.p. infusion. Subacute MPTP treatment significantly affected all aspects of the DA system within the nigral and striatal territories. In contrast, the 28-day chronic s.c. infusion did not significantly alter any components of the DA system. The 28- and 14-day chronic i.p. infusions induced loss of tyrosine hydroxylase (TH)-positive cells correlated with a decrease in Nurr1 mRNA levels, but no significant decrease in the density of TH striatal fibers. Importantly, however, only the 14-day chronic MPTP i.p. infusion protocol promoted the formation of neuronal inclusions as noted by the expression of alpha-synuclein protein within the cytoplasm of TH nigral neurons. Overall, we found that the 14-day chronic MPTP i.p. infusion reproduces more accurately the pathological characteristics of early stage Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457163     DOI: 10.1111/j.1471-4159.2009.06072.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  44 in total

1.  14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Authors:  H Ding; R Underwood; N Lavalley; T A Yacoubian
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 2.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

3.  Identification of Neurexophilin 3 as a Novel Supportive Factor for Survival of Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors.

Authors:  Kaneyasu Nishimura; Shigeo Murayama; Jun Takahashi
Journal:  Stem Cells Transl Med       Date:  2015-06-03       Impact factor: 6.940

Review 4.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

5.  6-OHDA-Lesioned Adult Zebrafish as a Useful Parkinson's Disease Model for Dopaminergic Neuroregeneration.

Authors:  Yuganthini Vijayanathan; Fei Tieng Lim; Siong Meng Lim; Chiau Ming Long; Maw Pin Tan; Abu Bakar Abdul Majeed; Kalavathy Ramasamy
Journal:  Neurotox Res       Date:  2017-07-13       Impact factor: 3.911

6.  Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions.

Authors:  Janelle Drouin-Ouellet; Anna-Liisa Brownell; Martine Saint-Pierre; Caroline Fasano; Vincent Emond; Louis-Eric Trudeau; Daniel Lévesque; Francesca Cicchetti
Journal:  Glia       Date:  2011-02       Impact factor: 7.452

Review 7.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

8.  Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.

Authors:  Hyung-Wook Kim; Won-Seok Choi; Noah Sorscher; Hyung Joon Park; François Tronche; Richard D Palmiter; Zhengui Xia
Journal:  Neurobiol Aging       Date:  2015-05-16       Impact factor: 4.673

9.  Motor Neurons Pathology After Chronic Exposure to MPTP in Mice.

Authors:  Giorgio Vivacqua; Francesca Biagioni; Carla L Busceti; Michela Ferrucci; Michele Madonna; Larisa Ryskalin; Shun Yu; Loredana D'Este; Francesco Fornai
Journal:  Neurotox Res       Date:  2019-11-13       Impact factor: 3.911

Review 10.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.